GH Research Reports 73% Remission in TRD with GH001; Global Pivotal Trial Set for 2026

Engagement with FDA on GH001 IND complete response ongoing The fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months...

July 25, 2025 | Friday | News
Matchpoint Therapeutics Secures Major Partnership with Novartis for Precision Covalent Inhibitor Development

Matchpoint to receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option ex...

July 25, 2025 | Friday | News
Clearside Biomedical Secures Health Canada Approval for XIPERE® in Treating Uveitic Macular Oedema

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...

July 25, 2025 | Friday | News
Cytiva Launches ÄKTA readyflux TFF System 500 to Advance Low-Volume Therapeutic Manufacturing

Cytiva, a Danaher company and a leader in the life sciences industry, is expanding its ÄKTA portfolio with the addition of a system designed to opti...

July 24, 2025 | Thursday | News
HMNC and Spruce Launch Phase 2 TAMARIND Trial to Explore Precision Treatment for Depression

HMNC Brain Health (“HMNC”), a global precision psychiatry biopharmaceutical company, in collaboration with Spruce Biosciences, Inc. (OTCQB: S...

July 23, 2025 | Wednesday | News
Rakovina Therapeutics Advances AI-Driven ATR Inhibitors in Fight Against Cancer

Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next...

July 23, 2025 | Wednesday | News
Longeveron Licenses Breakthrough Stem Cell Patent to Expand Cardiac Regenerative Pipeline

 Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, ra...

July 22, 2025 | Tuesday | News
Sanofi Completes Acquisition of Blueprint Medicines, Strengthening Rare Immunology Portfolio

Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a p...

July 21, 2025 | Monday | News
SpringWorks Wins EU Nod for EZMEKLY® in NF1-Related Tumours

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced  that the European Commission (EC) granted conditi...

July 21, 2025 | Monday | News
FDA Halts Sarepta’s Gene Therapy Trials After Deaths; Platform Designation Revoked Amid Safety Concerns

The U.S. Food and Drug Administration announced it has placed Sarepta Therapeutics investigational gene therapy clinical trials for limb girdle muscular ...

July 21, 2025 | Monday | Regulatory
10x Genomics and A*STAR GIS Launch Landmark Spatial Biology Study in Asia to Drive Cancer and Inflammation Breakthroughs

Ambitious study will profile thousands of tumor samples to uncover novel biomarkers and therapeutic targets for cancer and inflammatory diseases 10x Gen...

July 18, 2025 | Friday | News
Quetzal Therapeutics Launches with $50 Million to Advance Treatments for Rare and Life-Threatening Diseases

Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch with $50 million of committed capital. Founded to address u...

July 17, 2025 | Thursday | News
Amphista Therapeutics Reaches Discovery Milestone in Merck Collaboration for Next-Gen Protein Degraders

Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of next-generation, Targeted Protein Degradation (...

July 17, 2025 | Thursday | News
Acumen and JCR Pharmaceuticals Partner to Develop Enhanced Brain Delivery Therapy for Alzheimer’s Disease

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a ...

July 16, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close